Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a…

StudyActa psychiatrica Scandinavica· Jul 2024

Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.

Marie Reeberg Sass, Anne Mette Brandt Christensen, Margit Lykke Christensen … Anders Fink-Jensen

Forensic PsychiatryStudyTreatmentQ1IF 4.1

Only 46% of forensic psychiatric inpatients completed 26 weeks of liraglutide treatment.

Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.

Marie Reeberg Sass … Anders Fink-Jensen

Acta psychiatrica Scandinavica · Jul 2024 · Q1 in Psychiatry

Background

Overweight and obesity constitute a major concern among patients treated at forensic psychiatric departments.

Methods

Participants' baseline examinations were followed by a 26-week treatment period with liraglutide injection once daily according to a fixed uptitration schedule of liraglutide, with a target dose of 3.0 mg.

n = 24 participants

Results

46%

Fewer than half of patients stayed adherent to liraglutide through the full study period.

n = 24 participants

More results

Mean age: 42.3 [25th and 75th percentiles: 39.1; 48.4] years; body mass index (BMI): 35.7 [31.7; 37.5] kg/m 2 ; glycated haemoglobin (HbA1c): 37 [35; 39] mmol/mol.

For the completers, the median net body weight loss after 26 weeks of participation was -11.4 kg [-15.4; -5.9].

More results

The net difference in HbA1C and BMI was -2.0 mmol/mol [-4; -1] and -3.6 kg/m 2 [-4.7; -1.8], respectively.

The weight change and reduction in HbA1c and BMI were all statistically significant from baseline.

“

Conclusion · 1 of 2

The study did not confirm our hypothesis that liraglutide is a feasible treatment for a minimum of 75% of the patients initiating treatment with liraglutide while hospitalised in a forensic psychiatric department.

Conclusion · 2 of 2

The high dropout rate may be due to the non-naturalistic setting of the clinical trial. For the proportion of patients compliant with the medication, liraglutide 3.0 mg was an efficient treatment for overweight.

Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.

Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.

Related papers